The core case is premium compounding, not a step-change
rerating. BWXT already trades like a scarce nuclear asset, so most future value should come from converting
backlog, filling added
PCG capacity, attaching more lifecycle services and advancing defense-fuel optionality. That can still produce strong shareholder returns, but the stock is unlikely to behave like an early-stage nuclear developer because much of its moat is mature and already recognized.